Key Takeaways
- ONEOK raised its 2026 outlook for the third time this year on Oct. 27, and GSK declared a 17p quarterly dividend the next day, up from 16p a year earlier.
- GSK pays out 39% of its free cash flow as dividends, and ONEOK’s distributable cash flow covers its dividend more than twice over.
- ONEOK carries far more debt, at 3.7x EBITDA against 1.8x for GSK, while GSK pays out less in dividends than it did in fiscal 2021.
- Coming up are ONEOK’s 2027 guidance, due after its fourth-quarter results in February, and a reported $2.2 billion Zantac settlement at GSK.
ONEOK (OKE) raised its 2026 outlook for the third time this year on Oct. 27, on record volumes in the Permian Basin. A day later, GSK (GSK) declared a third-quarter dividend of 17p a share, up from 16p a year earlier, and said it expects 70p for the full year.
So both dividends are heading the right way, and each covers its payout comfortably on the measure that fits its business: free cash flow for a drugmaker, and distributable cash flow for a pipeline.
But 10 years is a long time to hold one stock. If I could only own one of these for the next decade, which dividend would I trust to keep growing?
| Metric | GSK (GSK) | ONEOK (OKE) |
|---|---|---|
| Dividend yield | 3.8% | 4.9% |
| Dividend growth, fiscal 2020-2025 | -12.0% a year | 2.0% a year |
| Dividend growth, fiscal 2025 | 4.9% (cash paid) | 4.0% |
| Coverage, latest | Cash dividend payout ratio: 39% (TTM to June 30, 2026) | Distributable cash flow coverage: 2.3x (fiscal 2025) |
| Net debt/EBITDA (LTM) | 1.8x | 3.7x |
| Interest coverage (LTM) | 14.7x | 3.5x |
Source: TIKR and StockAnalysis, at today’s prices. GSK’s figures are in pounds.
6 safe dividend stocks paying retirees 6%+ yields
There are over 100 stocks paying 6%+ annual dividends today.
But after an extensive investment review leveraging TIKR’s proprietary data, we now believe only six of them are truly safe for retirees.
They’re all yours as part of our new investment report. Learn more about how to get access right here.
GSK’s smaller dividend is well covered
GSK pays out less than it did a few years ago. Its dividends paid fell from £4.00 billion in fiscal 2021 to £2.25 billion in fiscal 2023. They’ve grown since, with cash dividends up 4.9% in fiscal 2025 to £2.56 billion.
GSK’s free cash flow has run well ahead of its dividends every year since fiscal 2016:

Free cash flow was £6.39 billion in fiscal 2025, against those £2.56 billion of dividends, for a cash dividend payout ratio of 40.1%. Over the twelve months to June 30, 2026, dividends took a well-covered 39% of £6.90 billion in free cash flow.
The business is growing, too. Third-quarter sales rose 5% to £8.9 billion, and GSK reaffirmed its full-year guidance.
The risk is a reported $2.2 billion Zantac settlement, a sizable but one-time bill. GSK also sets its dividend in pounds, so what a US holder collects moves with the exchange rate.
ONEOK has plenty of room to raise
GSK’s case rests on a clean balance sheet. ONEOK’s rests on growth. Its third-quarter adjusted EBITDA rose 6% from a year earlier to $2.24 billion, and it raised its 2026 adjusted EBITDA guidance to $8.5-$8.6 billion. On Oct. 6, it closed its purchase of Brazos Midstream’s Midland Basin assets.
ONEOK’s distributable cash flow per share has grown far faster than its dividend:

Distributable cash flow per share rose from $4.36 in fiscal 2020 to $9.25 in fiscal 2025. Over the same years, the dividend went from $3.74 to $4.12, so coverage climbed from 1.2x to 2.3x.
Management said the Brazos deal “accelerates ONEOK’s flexibility to increase capital returns to shareholders, including through potential dividend increases and share buybacks.” Those raises have plenty of room.
So which dividend wins?
If I can only own one of these for the next 10 years, it’s ONEOK.
At each stock’s five-year dividend growth rate, $10,000 in ONEOK would pay about $5,354 over the decade, against about $2,285 for GSK. But GSK’s five-year rate starts before its dividend fell, so it’s fairer to grow each dividend at its fiscal 2025 pace. On that basis, ONEOK pays about $5,894 over 10 years and GSK about $4,760, and GSK’s yearly check wouldn’t pass ONEOK’s for more than 30 years. GSK’s income here is figured in pounds.
ONEOK’s biggest weakness is its debt, and that’s coming down. The company extinguished nearly $5.5 billion of debt principal in September:

Total debt fell from $33.0 billion at June 30 to $28.5 billion at Sept. 30. On Oct. 19, S&P and Fitch upgraded ONEOK to BBB+ from BBB. TIKR puts net debt at 3.7x EBITDA, above the 3.5x that CFO Walter Hulse now calls “the upper end of our targeted leverage range.”
GSK’s dividend is safe. It has half ONEOK’s leverage, earns its interest 14.7x over, and pays out just 39% of its free cash flow, and the dividend is rising again. But for a 10-year hold, I’d rather own the bigger check, from a business whose distributable cash flow per share has more than doubled since fiscal 2020.
Of course, ONEOK won’t give 2027 guidance until after its fourth-quarter results in February, and a slowdown in the Permian would change the math.
Forget ONEOK: 6 safe 6%+ dividend yields you can buy right now
Dividends can hold the key to enormous wealth. But only if you buy the right ones.
Picking the right high-yield dividend stock can be the difference between a dream retirement…and scraping by every month, waiting for the next Social Security check to clear.
We’ve identified six stocks yielding 6%+ that we believe every retiree should know about right now. (And ONEOK isn’t one of them.)
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!